- Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
On 6ix: 6ix.com/news/phathom-pharmaceuticals-announces-positive-topline-results-from-phase-3-phalcon-nerd
Watch Phathom Pharmaceuticals' latest callPhathom Pharmaceuticals (NASDAQ:PHAT) Q3 2026 Earnings Call · Replay · Oct 29Read the transcript of Phathom Pharmaceuticals (NASDAQ:PHAT) Q3 2026 Earnings CallPhathom Pharmaceuticals, Inc. on 6ix
Story so far
- Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
- Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
- Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Earlier from Phathom Pharmaceuticals
- Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
- Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
- Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
- Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
Later from Phathom Pharmaceuticals
- Phathom Pharmaceuticals Provides Regulatory Updates
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
- Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
- Phathom Pharmaceuticals Reports First Quarter 2023 Results
Follow Phathom Pharmaceuticals into a list and get an email when it puts out news.
Follow Phathom Pharmaceuticals